TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $9.00.

HURA has been the topic of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Wall Street Zen lowered shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citizens Jmp began coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target on the stock. Finally, Citigroup began coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating for the company.

TuHURA Biosciences Stock Down 7.7%

TuHURA Biosciences stock opened at $2.28 on Tuesday. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43. The stock has a market cap of $145.19 million, a P/E ratio of -4.22 and a beta of -0.01. The company’s fifty day simple moving average is $2.29 and its 200-day simple moving average is $2.02.

TuHURA Biosciences (NASDAQ:HURA) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts expect that TuHURA Biosciences will post -0.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors have recently bought and sold shares of HURA. BlackRock Inc. acquired a new stake in shares of TuHURA Biosciences in the second quarter worth about $1,615,000. Geode Capital Management LLC increased its holdings in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after acquiring an additional 307,260 shares during the last quarter. Cetera Investment Advisers acquired a new position in shares of TuHURA Biosciences during the 1st quarter valued at about $251,000. Bank of New York Mellon Corp bought a new position in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $285,000. Finally, WealthShield Partners LLC acquired a new stake in TuHURA Biosciences in the 1st quarter worth approximately $164,000. 0.62% of the stock is currently owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.